Clinical trials: Kidney Disorder
ESRD, Diabetes
IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
Primary Objective: To demonstrate that use of glucose sparing prescriptions (PEN vs Dianeal only) in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD)patients…
- Conditions
- ESRD, Diabetes, CAPD, APD
- Trial name
- Impendia (NCT00567489)
- Testing
- Physioneal, Dianeal, Extraneal
- Where
- 19 sites in Hong Kong, Russia and 3 more
- Volunteers
- 137 people
- Sponsor
- Vantive Health LLC
Renal Cell Cancer, Kidney Cancer
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
The goal of this clinical research study is to learn the effectiveness of Sutent® (sunitinib malate, SU011248) in the treatment of patients with non-clear cell renal cell cancer.
- Trial name
- NCT00465179
- Testing
- Sunitinib Malate
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
End Stage Renal Disease (ESRD)
Performance Evaluation of the AMIA APD Solution Generation System in Patients End Stage Renal Disease (ESRD)
Peritoneal dialysis (PD) is a well-established treatment for renal failure including long-term management of end stage renal disease (ESRD) by continuous ambulatory peritoneal dialysis or automated peritoneal dialysis (APD).
- Trial name
- NCT03812679
- Testing
- AMIA APD Solution Generation System
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- Vantive Health LLC
Atypical Hemolytic Uremic Syndrome
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.
- Trial name
- COMMUTE-a (NCT04861259)
- Testing
- Crovalimab
- Where
- 41 sites in United States, Belgium and 14 more
- Volunteers
- 83 people
- Sponsor
- Hoffmann-La Roche
Clear Cell Renal Carcinoma
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
The purpose of this trial is to determine if adjuvant therapy with axitinib will prevent or delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high risk patients.
- Trial name
- ATLAS (NCT01599754)
- Testing
- Axitinib
- Where
- 106 sites in United States, China and 7 more
- Volunteers
- 724 people
- Sponsor
- SFJ Pharma Ltd. II
Diabetic Kidney Disease
Rhubarb and Angiotensin Converting Enzyme Inhibitor
Rhubarb extract is a chinese herbal preparation that is used in china and other asian countries to treat constipation and chronic kidney disease.
- Trial name
- RACE II (NCT00672451)
- Testing
- rhubarb extract
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Wake Forest University
End Stage Renal Disease, Thrombosis
Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis
This study evaluates the safety and efficacy of AB023 (xisomab 3G3) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts.
- Trial name
- NCT03612856
- Testing
- AB023- Dose 1, AB023-Dose 2
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Aronora, Inc.
Hypertension, Chronic Kidney Disease
Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan
Purpose of this study 1. Intensive education for low salt diet will be enhance the anti-proteinuric effect of Olmesartan, a popular anti-hypertensive drug of angiotensin II receptor blocker, in Koreans compared to conventional…
- Conditions
- Hypertension, Chronic Kidney Disease, Microalbuminuria
- Trial name
- ESPECIAL (NCT01552954)
- Testing
- Intensive education of low salt diet
- Where
- 7 sites in South Korea
- Volunteers
- 269 people
- Sponsor
- Seoul National University Bundang Hospital
Secondary Hyperparathyroidism
FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
FGF-23 is a newly described protein that is an important regulator of phosphorus in the body. This protein increases in people with kidney disease and people who need dialysis have very high levels of FGF-23 in the blood.
- Trial name
- NCT00999037
- Testing
- Sevelamer Carbonate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, Los Angeles
Primary Hyperoxaluria Type 1 (PH1)
Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of lumasiran in healthy adult volunteers and subjects…
- Trial name
- NCT02706886
- Testing
- Lumasiran
- Where
- 9 sites in France, Germany and 3 more
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Graft vs Host Disease, Kidney Transplantation
Study Evaluating Sirolimus in Kidney Transplant Recipients
The purpose of this study is to compare the kidney function in patients who have received a transplanted kidney and were treated with the combination of sirolimus, daclizumab, mycophenolate and corticosteroids versus transplanted…
- Trial name
- NCT00195273
- Testing
- sirolimus, cyclosporine, mycophenolate mofetil
- Where
- 3 sites in Norway, Sweden
- Volunteers
- 61 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Chronic Kidney Disease, Vitamin D Deficiency
Vitamin D and Coronary Calcification Study
Patients with chronic kidney disease (CKD) have a higher mortality rate than the general population, with cardiovascular disease (CVD) accounting for approximately 50% of deaths.
- Conditions
- Chronic Kidney Disease, Vitamin D Deficiency, Coronary Calcification, Disorders of Calcium and Bone Metabolism
- Trial name
- VCOR (NCT00752102)
- Testing
- Calcitriol (Rocaltrol®), Paricalcitol
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Joslin Diabetes Center
Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis
The primary objectives of this study were to determine the rate, extent, and routes of radioactivity excretion of [¹⁴C]etelcalcetide in feces, dialysate, and urine over time and to measure radioactivity concentrations in whole…
- Trial name
- NCT02054572
- Testing
- [¹⁴C]Etelcalcetide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Amgen
Chronic Hepatitis C, Renal Impairment
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
Grazoprevir (MK-5172) and Elbasvir (MK-8742) were studied as the principal components of combination oral therapy for hepatitis C virus (HCV).
- Trial name
- NCT01937975
- Testing
- Grazoprevir, Elbasvir
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pruritis
A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients
Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective.
- Trial name
- CRN11 (NCT01114672)
- Testing
- 50,000 Units Ergocalciferol
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Winthrop University Hospital
Healthy
Biological Basis of Individual Variation in Social Cooperation
The project has three overall objectives. The first is to determine whether and how administration of intranasal oxytocin (OT) and intranasal vasopressin (AVP) influence cooperative decision-making and neural responses to…
- Trial name
- NCT01566539
- Testing
- Intranasal Oxytocin (OT) 24 IU, Intranasal Vasopressin (AVP), Intranasal Vasopressin (AVP) 40 IU
- Where
- 2 sites in United States
- Volunteers
- 707 people, healthy volunteers welcome
- Sponsor
- Emory University
Type 2 Diabetes Mellitus, Cardiovascular Disease
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)
The purpose of this study was to determine whether, in patients with type 2 diabetes and pre-existing disease of the heart and the circulatory system and/or the kidney, aliskiren at a target dose of 300 mg once daily (compared to…
- Trial name
- ALTITUDE (NCT00549757)
- Testing
- Aliskiren
- Where
- 776 sites in United States, Argentina and 35 more
- Volunteers
- 8,606 people
- Sponsor
- Novartis Pharmaceuticals
Anaemia
Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)
Daprodustat has demonstrated an ability to effectively raise hemoglobin concentrations with lower erythropoietin (EPO) levels than those observed after administration of recombinant human erythropoietin (rhEPOs).
- Trial name
- NCT03446612
- Testing
- Daprodustat, Darbepoetin alfa, Acetylcholine
- Where
- 3 sites in United Kingdom
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease, Iron-deficiency Anemia
A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease
The long-term goal is to assess the fall in kidney function measured by glomerular filtration rate (GFR) when patients with chronic kidney disease (CKD) are exposed to intravenous iron (IVIR).
- Trial name
- NCT00830037
- Testing
- IV Iron, Ferrous Sulfate
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Indiana University
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma
- Trial name
- NCT03220035
- Testing
- Laboratory Biomarker Analysis, Vemurafenib
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.